CYP1A2*F Polymorphism contributes at least partially to the Variability of Plasma Levels of Dehydroaripiprazole, an active Metabolite of Aripiprazole, in Schizophrenic Patients.
Takeshi SuzukiGoyo NagaiKazuo MiharaYoko TomoriShoko KagawaAkifumi NakamuraKenji NemotoTsuyoshi KondoPublished in: Drug metabolism and bioanalysis letters (2023)
The findings of this study suggest that the CYP1A2*F polymorphism contributes at least partially to the variability in the steady-state plasma levels of dehydroaripiprazole.